# Internal Review â€” Round 2

**Role:** Internal review (Editor mode)
**Paper:** paper.pdf
**Timestamp:** 2026-02-11T18:25:00

---

## Review Summary

The paper has been substantially revised from v5. Key improvements include:

1. **Structural overhaul:** 10 sections reduced to 9; Robustness consolidated from 9 subsections to 3
2. **Prose quality:** Complete Shleifer-style rewrite of Introduction (5 pages of flowing narrative)
3. **New empirical content:** Commercial sector, industrial placebo tabulated, COVID robustness
4. **New references:** Metcalf & Hassett (1999), Mildenberger et al. (2022), Abadie et al. (2010)

All major reviewer concerns from v5 have been addressed or discussed. The paper is ready for external review.

DECISION: MINOR REVISION
